Immunovant (IMVT) Research & Development (2018 - 2026)
Immunovant's Research & Development came in at $142.63 million for fiscal Q1 2027 (quarter ended Jun 30, 2026), up 40.9% from $101.2 million a year earlier and up 0.2% from the prior quarter.
Immunovant (IMVT) Research & Development (2018 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Immunovant reported Research & Development of $498.09 million, up 28.8% year-over-year; for FY2026 (ended Mar 31, 2026), it came in at $456.66 million, up 26.5% from FY2025.
- Research & Development has increased in each of the last seven fiscal years, with a five-year compound annual growth rate of 46.1% (FY2021 to FY2026).
- Going back by fiscal year, Research & Development was $360.92 million in FY2025 (+69.5%), $212.93 million in FY2024 (+32.9%), $160.26 million in FY2023 (+57.4%) and $101.81 million in FY2022 (+48.4%).
- The fiscal Q1 2027 figure represents the highest quarterly Research & Development in data going back to fiscal Q3 2019.
- Year-over-year, Research & Development has increased for 24 consecutive quarters, with growth averaging 48.7% over the last eight quarters.
- The year-over-year growth in Research & Development has ranged between 4.7% (fiscal Q3 2026) and 102.8% (fiscal Q2 2025) over the last five years.
- Business Quant data shows IMVT's Research & Development at $142.29 million (Q4 2026), $98.92 million (Q3 2026) and $114.25 million (Q2 2026) in the three fiscal quarters before Q1 2027.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Immunovant | 6.91 Bn | 6.91 Bn | - | 142.63 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 142.63 Mn |
| Mar 31, 2026 | 142.29 Mn |
| Dec 31, 2025 | 98.92 Mn |
| Sep 30, 2025 | 114.25 Mn |
| Jun 30, 2025 | 101.20 Mn |
| Mar 31, 2025 | 93.65 Mn |
| Dec 31, 2024 | 94.52 Mn |
| Sep 30, 2024 | 97.27 Mn |
| Jun 30, 2024 | 75.47 Mn |
| Mar 31, 2024 | 66.06 Mn |
| Dec 31, 2023 | 48.34 Mn |
| Sep 30, 2023 | 47.96 Mn |
| Jun 30, 2023 | 50.58 Mn |
| Mar 31, 2023 | 51.84 Mn |
| Dec 31, 2022 | 42.25 Mn |
| Sep 30, 2022 | 37.74 Mn |
| Jun 30, 2022 | 28.43 Mn |
| Mar 31, 2022 | 31.99 Mn |
| Dec 31, 2021 | 29.76 Mn |
| Sep 30, 2021 | 21.36 Mn |
Immunovant Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=IMVT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "IMVT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=IMVT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();